BACKGROUND: Loss of phosphatase and tensin homologue deleted in chromosome 10 (PTEN) function in advanced colorectal cancer (CRC) may represent one of the resistance mechanisms to cetuximab by interfering with the epidermal growth factor receptor signal transduction pathway. METHODS: PTEN expression tested by indirect immunofluorescence was evaluated both on primary (n¼43) and on metastatic (n¼24) sites in CRC patients treated with cetuximab. RESULTS: The loss of PTEN expression tested on metastatic sites was negatively associated with response (100% progressive disease (PD) in PTEN-negative cases vs 30% PD in PTEN-positive cases; Po0.05), PFS (0.8 vs 8.2 months; Po0.001) and OS (2.9 vs 14.2 months; Po0.001). CONCLUSION: A potential role of PTEN in the anti-tumour activity of cetuximab could be hypothesised.
PTEN status in advanced colorectal cancer treated with cetuximab / Negri, F. V.; Bozzetti, C.; Lagrasta, Costanza Anna Maria; Crafa, Pellegrino; Bonasoni, M. P.; Camisa, R.; Pedrazzi, Giuseppe; Ardizzoni, A.. - In: BRITISH JOURNAL OF CANCER. - ISSN 0007-0920. - 102:(2010), pp. 162-164. [10.1038/sj.bjc.6605471]
PTEN status in advanced colorectal cancer treated with cetuximab
F.V. Negri;LAGRASTA, Costanza Anna Maria;CRAFA, Pellegrino;PEDRAZZI, Giuseppe;
2010-01-01
Abstract
BACKGROUND: Loss of phosphatase and tensin homologue deleted in chromosome 10 (PTEN) function in advanced colorectal cancer (CRC) may represent one of the resistance mechanisms to cetuximab by interfering with the epidermal growth factor receptor signal transduction pathway. METHODS: PTEN expression tested by indirect immunofluorescence was evaluated both on primary (n¼43) and on metastatic (n¼24) sites in CRC patients treated with cetuximab. RESULTS: The loss of PTEN expression tested on metastatic sites was negatively associated with response (100% progressive disease (PD) in PTEN-negative cases vs 30% PD in PTEN-positive cases; Po0.05), PFS (0.8 vs 8.2 months; Po0.001) and OS (2.9 vs 14.2 months; Po0.001). CONCLUSION: A potential role of PTEN in the anti-tumour activity of cetuximab could be hypothesised.| File | Dimensione | Formato | |
|---|---|---|---|
|
PTEN status in advanced colorectal cancer treated with cetuximab.doc
non disponibili
Tipologia:
Abstract
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
21 kB
Formato
Microsoft Word
|
21 kB | Microsoft Word | Visualizza/Apri Richiedi una copia |
|
PTEN-status-in-advanced-colorectal-cancer-treated-with-cetuximab_2010_British-Journal-of-Cancer.pdf
non disponibili
Tipologia:
Documento in Post-print
Licenza:
NON PUBBLICO - Accesso privato/ristretto
Dimensione
293.08 kB
Formato
Adobe PDF
|
293.08 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
